Form 4: Forte Biosciences Insider Trades Common Stock and RSUs

Forte Biosciences CFO Antony A. Riley reports transactions involving common stock and restricted stock units, including acquisitions and disposals.

Summary

• Antony A. Riley, Chief Financial Officer of Forte Biosciences, Inc., reported transactions on July 1, 2026.
• Riley acquired 375 shares of Common Stock through Restricted Stock Units (RSUs).
• Following these transactions, Riley beneficially owns 42,734 shares of Common Stock.
• Riley also disposed of 134 shares of Common Stock for $21.32 per share, resulting in beneficial ownership of 42,600 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine insider transactions related to compensation and personal financial management, without significant positive or negative strategic implications.

Positives

• Acquisition of 375 shares of Common Stock via RSUs, indicating continued equity participation.
• The CFO's holdings remain substantial at 42,734 shares after the reported transactions.

Negatives

• Disposal of 134 shares of Common Stock, which could be interpreted as a reduction in direct holdings.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive equity dealings. The specific details of acquisitions and disposals by a CFO can offer insights into management's confidence in the company's prospects.

Stakeholder Impact

• Shareholders: The transactions provide transparency into executive equity holdings, which can influence investor perception.
• Employees: The RSU acquisition is part of the executive compensation structure, reflecting the company's incentive programs.

Key Dates

Keywords

Forte Biosciences, FBRX, Form 4, Insider Trading, Common Stock, Restricted Stock Units, RSU, Beneficial Ownership, CFO, Antony A. Riley